Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction (MUSIC-HFpEF)

Sardocor

Status and phase

Enrolling

Phase 1

Conditions

Heart Failure, Diastolic

Heart Failure With Preserved Ejection Fraction

Treatments

Biological: AAV1/SERCA2a

Study type

Interventional

Funder types

Industry

Identifiers

NCT06061549

SRD-001-1003

Details and patient eligibility

About

The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are:

safety and tolerability of the gene therapy; and
whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effects on left-sided filling pressures while exercising. The first year will have multiple in-person visits followed by 4 years of biannual phone calls.

Full description

Eligible participants will undergo a one-time antegrade epicardial coronary artery infusion of gene therapy delivered to the 3 major cardiac territories of the left ventricle of the heart (anterior, lateral, inferior/posterior) or bypass grafts unless contraindicated. Post-procedure, the subject will be monitored continuously for a minimum of 4 hours and then discharged to home that same day if medically appropriate. Participants will be followed for 52 weeks as part of the main trial. On Day 2 and Week 1, subjects will be contacted by phone for a general safety assessment, and if clinically indicated, an in-person evaluation and assessment will be performed as soon as possible. On Weeks 2, 4, 12, 24 and 52, subjects will undergo general safety assessments. Additionally, at Weeks 24 and 52, subjects will undergo outpatient core resting and exercise transthoracic echocardiography, right heart catheterization with hemodynamic monitoring and gas exchange measurements, 6-minute wall test, cardiac biomarker testing and completion the Kansas City Cardiomyopathy Questionnaire. Upon completion of the active observation period, participants will continue to be followed for 4 years with bi-annual, semi-structured telephone or in-person questionnaires that collect information on overall status and other comorbid conditions of interest in gene therapy trials.

Enrollment

10 estimated patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Willing and able to provide informed consent
Negative for anti-AAV1 neutralizing antibodies
NYHA class II or III
Left ventricular ejection fraction ≥ 50%
Evidence of resting or exercise-induced left ventricle filling pressure
On oral diuretic therapy
Adequate birth control

Exclusion criteria

NYHA class IV
Heart failure requiring hospitalization in the past 3 months
Manifested or provocable ischemic heart disease
Atrial fibrillation
History of congenital heart disease, restrictive or infiltrative cardiomyopathy, hypertrophic cardiomyopathy, acute myocarditis, pericardial disease, uncorrected thyroid disease or discrete left ventricular (LV) aneurysm
History of amyloidosis
Untreated left-sided valvular disease
Severe COPD
BMI > 50 kg/m^2
Severe liver, kidney or hematologic dysfunction
Cancer within the past 5 years
Unstable concurrent conditions